Loading
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Previous close
$13.44
+$0.15 · +1.13%
Regular session · ET · Market data may be delayed.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Day range
Current $13.44
52-week range
Current $13.44
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
39
Expensive
Sentiment
57
Mixed
Risk
53
Elevated Risk
Momentum
30
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Day range
Current $13.44
52-week range
Current $13.44
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 16.96M USD | 20.22M USD | 18.69M USD | 26.5M USD | 23.76M USD |
| Cost of goods sold | 13.71M USD | 17.59M USD | 15.11M USD | 13.33M USD | 14.99M USD |
| Gross profit | 3.25M USD | 2.63M USD | 3.58M USD | 13.17M USD | 8.77M USD |
| Research and development | 14.32M USD | 8.88M USD | 7.47M USD | 10.18M USD | 10.26M USD |
| Selling, general, and administrative | 13.93M USD | 12.91M USD | 11.38M USD | 10.37M USD | 9.45M USD |
| Operating expenses | 28.53M USD | 22.02M USD | 19.08M USD | 20.83M USD | 19.99M USD |
| Interest income | 1.86M USD | 2.05M USD | 2.34M USD | 270K USD | 11K USD |
| Interest expense | 663K USD | 561K USD | 335K USD | 162K USD | 167K USD |
| Depreciation and amortization | 1.86M USD | 1.48M USD | 1.3M USD | 1.27M USD | 1.24M USD |
| Operating income | −25.28M USD | −19.38M USD | −15.5M USD | −7.66M USD | −11.22M USD |
| Net income | −23.88M USD | −30.22M USD | −6.72M USD | −19.6M USD | −13.55M USD |
Company facts updated Sep 9, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$26.00
93.45% upsideFunds reporting this stock among their holdings, ordered by reported position size.
iShares Russell 2000 ETFIWM3.13M0.00%80.51B USD0.19%$294.67-0.45%
ARK Israel Innovative Technology ETFIZRL1.95M1.43%136.9M USD0.49%$29.00-0.97%
iShares Russell 2000 Growth ETFIWO1.2M0.01%14.7B USD0.24%$377.11-0.11%
Vanguard Russell 2000 ETFVTWO814.16K0.00%17.4B USD0.06%$119.14-0.40%
iShares Micro-Cap ETFIWC451.36K0.03%1.49B USD0.60%$195.17-0.74%
iShares Russell 3000 ETFIWV176.96K0.00%20.48B USD0.20%$435.65-0.56%
Vanguard Russell 2000 Growth ETFVTWG147.55K0.01%1.7B USD0.06%$275.33-0.12%
Invesco NASDAQ Future Gen 200 ETFQQQS103.6K0.45%22.81M USD0.20%$44.1851-1.26%iShares Russell 2000 ETFIWMARK Israel Innovative Technology ETFIZRLiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCiShares Russell 3000 ETFIWVVanguard Russell 2000 Growth ETFVTWGInvesco NASDAQ Future Gen 200 ETFQQQSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
